Small increases in those MSK codes are definitely not necessarily drug side effects: they could come from more clinic contact, detection bias, miscoding, activity-related aches during weight loss, or unmasking old pains as people move more
Future directions: clinical trials and emerging therapies Clinical trial focus on AR (synergistic combination and novel agonists) Ongoing clinical trials prioritize receptor-specific modulation to enhance therapeutic efficacy while minimizing systemic adverse effects
Helveticus (P2-14) [85, 86, 89], Polydextrose + Galactooligosaccharide (P21-W13/W14) [90], or a mix of Polydextrose + Galactooligosaccharide and L
Trouble swallowing
GLP-1 receptor knockout and GIP receptor knockout mice for mechanism delineation Receptor binding studies: Human, mouse, and rat receptor-expressing cell lines In vitro systems: Primary hepatocytes for gluconeogenesis studies
Outcomes were separately assessed by age groups, sex, and race